Home Respicardia Inc.

Respicardia Inc.

Treatment Benefits of the remedē® System Sustained Through 36 Months in Patients with Central Sleep Apnea

The remedē System, which received U.S. Food and Drug Administration (FDA) approval in October 2017, is a breakthrough implantable system that treats the harmful effects of central sleep apnea by restoring a more normal breathing pattern during sleep.

Respicardia Closes $58.5 Million In Financing To Treat Central Sleep Apnea

12/18/17: Respicardia, Inc., a private medical technology company, announced today that the company has closed a $58.5 million financing, led by ZOLL Medical Corporation, a leading manufacturer of medical devices and related software solutions. All of Respicardia's existing major investors helped to complete the financing round.

Must Read

New Research Demonstrates Advantages of ExactechGPS® for Knee and Shoulder Joint Replacement

ExactechGPS is a dynamic computer-assisted technology that enhances the surgical experience with active intraoperative feedback for real-time execution in a compact and mobile system within the sterile field.

Merry X-Ray Corporation Announces Significant Shift in Their Sales and Marketing Strategies

The company will be consolidating all of their existing companies and acquisitions past and present under one strong umbrella identity: MXR The Imaging Solution Company.